Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
about
The molecular biology, biochemistry, and physiology of human steroidogenesis and its disordersNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignEvaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouseEndpoints in phase II trials for advanced non-small cell lung cancer.A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumabInitial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancerClinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma.Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancerThe BATTLE trial: personalizing therapy for lung cancer.The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapySelection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies.Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.New imaging approaches for understanding lung cancer response to treatment.Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsAutocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network.Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741The power of phase II end-points for different possible mechanisms of action of an experimental treatmentThe Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer.Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancerTherapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies.The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.Clinical trial designs incorporating predictive biomarkers.Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.When progressive disease does not mean treatment failure: reconsidering the criteria for progression.Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.Controlled multi-arm platform design using predictive probability.Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyBayesian adaptive randomization designs for targeted agent development.
P2860
Q24613957-6B1B7CCC-A2B5-47FC-A7FA-4695234AADC9Q27003440-4F31B587-EDA5-4F01-9C36-6B2901EF02A5Q30754691-CCFE8E4C-8344-43C2-BFA4-0DA6190DC7B5Q33557040-BD4161BF-A63C-45D7-A967-0D339E2821F5Q33685254-A61AB232-69D2-47C1-98FA-F2F94C72BF7DQ33771180-10D37189-C007-47D1-A98F-12F79C79505DQ33822393-99F54DE1-440D-4187-A1BF-4BDBC29E174EQ33827699-8D9A0A24-67D4-4321-9C3A-E97576753252Q33911180-7A2B4004-6CBF-4B88-8777-AC03A08F2182Q33938637-62117836-0FFC-4F57-BA69-C98D449E23D1Q34094103-A5F97493-1550-4AA4-84E7-BC706869DDB1Q34134408-07AF0E54-E384-44FB-AA0A-3E721059A25FQ34243500-ED8AD4F8-20E0-4FDA-AB81-B73C43C8242EQ34275011-332C653D-607E-460A-8E95-1CAE86D3B44CQ34720945-88E4D03A-715A-4EE4-BB8A-109C078FC00CQ34769741-D9E505BA-5AC8-4E9A-B2B8-CE9E65E7548CQ35190735-C6CB5609-A1C8-4053-B70A-E4E3A3C389ACQ35200105-3BB1575A-AF9B-462E-9FD2-D6F530661A51Q35375761-0051D25B-D94C-41DE-8A8F-32CAA136B083Q35583019-062B8613-672A-466D-920A-C985F09192C2Q35583855-BDD4DE40-DCF1-4FC4-9A88-822BBC7C6BA9Q35584533-C5436D5F-0D93-4908-A57A-26A4917700F7Q35584926-04739DB8-7A1C-44C9-A8C8-5E6EA8537CDCQ35619065-031BCE52-F4BD-477A-9E07-FE5B3A6D49DCQ35835931-489EE4EA-1DA4-438C-98D6-8C8156A1993CQ35870217-B286CB52-5397-4B08-BDAF-407FF3C61F20Q35876285-E77EBB9C-4543-415B-8B51-C1D4B0FF0951Q36088918-C3EE0690-119D-4914-A34E-276CA65C79D1Q36197811-FD80CABB-7D72-4E10-B284-E26B225DC865Q36353287-C4878CB0-92EF-4050-AA7C-739EF49A7CB1Q36534713-13D60B34-3D46-498A-A9E2-AE71689C7697Q36599208-35277C9E-C529-4C79-A80E-4A6711B5FF74Q36680046-37CC6F68-7175-4B5B-BEDA-728CDD604135Q36738554-C4C17176-C8CF-4B71-931F-D0FA055AE593Q37003248-09C6E400-CD78-4059-BB5A-9905A7A42D7AQ37021940-6C091A78-DCDA-4E98-870F-3F622FF97D3FQ37289826-8DDFD5A5-48B1-4A2D-83BF-DFF60CD168EDQ37344500-940DFC6C-2E79-49D0-8CEF-33A9C95A421CQ37347532-1C4F0E20-BBA5-4B02-96E1-CFA07DF35F5DQ37415504-2A995166-F12E-45B0-B434-A6E402D84FDD
P2860
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Disease control rate at 8 week ...... ology Group randomized trials.
@en
Disease control rate at 8 week ...... ology Group randomized trials.
@nl
type
label
Disease control rate at 8 week ...... ology Group randomized trials.
@en
Disease control rate at 8 week ...... ology Group randomized trials.
@nl
prefLabel
Disease control rate at 8 week ...... ology Group randomized trials.
@en
Disease control rate at 8 week ...... ology Group randomized trials.
@nl
P2093
P50
P356
P1476
Disease control rate at 8 week ...... ology Group randomized trials.
@en
P2093
John J Crowley
Martin J Edelman
Mary W Redman
Primo N Lara
Stephen K Williamson
P304
P356
10.1200/JCO.2007.13.0344
P407
P577
2008-01-01T00:00:00Z